Furthermore, a case report in NSCLC demonstrated that the ALK I1171N mutation, along with other ALK amino acids substitutions identified in this study, conferred resistance to ensartinib but remained sensitive to lorlatinib, further supporting the efficacy of lorlatinib against multiple ALK amino acids substitutions (Ye and Guo, 2023). The gene discussed is ALK; the disease is non-small cell lung carcinoma.